Lexaria Bioscience Corp.
LEXXLexaria Bioscience Corp. in brief
Lexaria Bioscience Corp. is a listed company in the Biotechnology industry, based in Canada. Its market value was $15 M on 1 August 2026, which makes it the 25,048th largest listed company in the world and the 1,255th largest in Canada on this site. In the year to August 2025 it had sales of $1 M and a net loss of $12 M. Richard Christopher is its chief executive. Its largest product and service lines by sales in 2025 were IP Licensing (99%) and B2B (1%). Its shares trade under the symbol LEXX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs and glucose-dependent insulinotropic polypeptide drugs, vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
From the company's annual report filed with the US SEC: read the report
Lexaria Bioscience Corp. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- ✎Renamed Lexaria Bioscience Corp.Formerly Lexaria Corp..
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 8 years on record.
Events of Lexaria Bioscience Corp. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #1,220 (Jan 2022) · #1,198 (Dec 2022) · #1,368 (Jul 2023) · #1,133 (Jan 2024) · #51 (Mar 2026) · #802 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 21.1×
- Price / book
- 5.0×
- Free cash flow yield
- -69.8%
- Net margin
- -1676.1%
- Operating margin
- -1673.2%
- Return on equity
- -398.0%
- Liabilities / assets
- 37.6%
- Revenue growth
- +54.3%
- R&D / revenue
- 1160.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Aug 2025 | $1M | +54.3% | $-12M | $-12M | -1676.1% |
| Aug 2024 | $0M | +100.0% | $-6M | $-6M | -1260.9% |
| Aug 2023 | $0M | -11.5% | $-7M | $-7M | -2895.7% |
| Aug 2022 | $0M | -63.9% | $-7M | $-7M | -2796.2% |
| Aug 2021 | $1M | +132.3% | $-6M | $-4M | -559.7% |
| Aug 2020 | $0M | +40.9% | — | $-4M | -1316.1% |
| Aug 2019 | $0M | -48.8% | — | $-4M | -1890.9% |
| Aug 2018 | $0M | — | — | $-7M | -1537.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Aug 2025 | $-10M | $0M | $-10M | $-0.66 | — |
| Aug 2024 | $-5M | $0M | $-5M | $-0.47 | — |
| Aug 2023 | $-6M | $0M | $-6M | $-1.01 | — |
| Aug 2022 | $-5M | $0M | $-5M | — | — |
| Aug 2021 | $-4M | — | — | $-0.95 | — |
| Aug 2020 | $-3M | $0M | $-3M | $-1.47 | — |
| Aug 2019 | $-3M | $1M | $-4M | $-0.05 | — |
| Aug 2018 | $-3M | — | — | $-0.09 | — |
Quarterly results
Latest quarter to May 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to May 2026.
SEC filings
- Sep 9, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Sep 1, 20268-KCurrent reportOther events
- Aug 17, 20268-KCurrent reportOther events
- Aug 10, 20268-KCurrent reportListing notice
- Jul 30, 20268-KCurrent reportBylaws amended
- Jul 13, 202610-QQuarterly report · period to May 2026
- Apr 13, 202610-QQuarterly report · period to Feb 2026
- Feb 6, 20268-KCurrent reportListing notice
- Jan 28, 20268-KCurrent reportShareholder vote
- Jan 13, 202610-QQuarterly report · period to Nov 2025
- Dec 16, 20258-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Dec 10, 2025DEF 14AProxy statement
Official filings of Lexaria Bioscience Corp. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-12 M
- Net income
- $-12 M
For year ending August-2025 · source: SEC filing
Balance sheet
- Total assets
- $4 M
- Total liabilities
- $2 M
- Total equity
- $3 M
As of August-2025
Top 15 institutional investors in Lexaria Bioscience Corp.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 172,084 | New | 0.69% | $1 M | Nov 16, 2026 |
| 2 | Invenomic Capital Management LP | 21,578 | New | 0.09% | $0 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 19,896 | New | 0.08% | $0 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 16,689 | New | 0.07% | $0 M | Nov 6, 2026 |
| 5 | UBS Group AG | 12,821 | New | 0.05% | $0 M | Nov 10, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 6,278 | New | 0.03% | $0 M | Nov 13, 2026 |
| 7 | Toronto Dominion Bank | 2,000 | New | 0.01% | $0 M | Nov 16, 2026 |
| 8 | BlackRock, Inc. | 1,829 | New | 0.01% | $0 M | Nov 13, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 1,778 | New | 0.01% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Global Advisers, LLC | 681 | New | 0.00% | $0 M | Nov 13, 2026 |
| 11 | Royal Bank Of Canada | 478 | New | 0.00% | $0 M | Nov 16, 2026 |
| 12 | Osaic Holdings, Inc. | 119 | New | 0.00% | $0 M | Nov 12, 2026 |
| 13 | Federation des caisses Desjardins du Quebec | 24 | New | 0.00% | $0 M | Nov 16, 2026 |
| 14 | FMR LLC | 2 | New | 0.00% | $0 M | Nov 10, 2026 |
| 15 | Danske Bank A/s | 1 | New | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Lexaria Bioscience Corp.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 298,436 | $0 M | 0.78% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 171,896 | $0 M | 0.45% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 Invenomic FundInvenomic Capital Management LP | 99,986 | $0 M | 0.26% | <0.01% | −45% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 31,892 | $0 M | 0.08% | <0.01% | +17% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 26,138 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 11,622 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lexaria Bioscience Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Christopher BunkaDirector | Gift | -100,000 | — | — | 273,543 | Form 4 |
| filed | Christopher BunkaDirector | Buyindirect | +11,900 | $0.910 | $11 K | 281,912 | Form 4 |
| filed | Christopher BunkaDirector | Buyindirect | +15,600 | $0.920 | $14 K | 270,012 | Form 4 |
| filed | John Martin DochertyPresident & CSO, Director | Buy | +5,376 | $0.930 | $5 K | 5,376 | Form 4 |
| filed | William Edward McKechnieDirector | Buy | +5,000 | $0.910 | $5 K | 18,191 | Form 4 |
| filed | Richard ChristopherChief Executive Officer, Director | Buy | +15,000 | $0.910 | $14 K | 65,000 | Form 4 |
| filed | Vanessa CarleSecretary | Buy | +750 | $0.910 | $683 | 750 | Form 4 |
| filed | Christopher BunkaDirector | Grant or award | +100,000 | — | — | 373,543 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lexaria Bioscience Corp.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1.1-for-1 split
Trading halts
- 2026-10-09 18:07 UTC, code LUDP, resumed 18:12 UTC
- 2026-08-03 13:59 UTC, code LUDP, resumed 14:04 UTC
- 2026-07-31 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 1,615 shares at $3.77
- : 153 shares at $3.30
- : 568 shares at $3.22
- : 2,647 shares at $3.08
- : 1,311 shares at $2.65
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lexaria Bioscience Corp. scorecard#
Passes 1 of the 10 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.66 vs -0.47Diluted EPS -0.66 in fiscal 2025 against -0.47 the year before (report's currency).
- ✗Net income higher than five years earlier-$12 M-$12 M in fiscal 2025 against -$4 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-215.8%-215.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.3×Current ratio 2.33 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-24.16Z-score -24.16 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year45.3%Diluted shares up 45.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Lexaria Bioscience Corp.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Aug 31, 2025 | FY 2024to Aug 31, 2024 | FY 2023to Aug 31, 2023 | FY 2022to Aug 31, 2022 | FY 2021to Aug 31, 2021 | FY 2020to Aug 31, 2020 | FY 2019to Aug 31, 2019 | FY 2018to Aug 31, 2018 | FY 2017to Aug 31, 2017 | FY 2016to Aug 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 706+52.0%100% | 464+105%100% | 226−11.4%100% | 255−64.7%100% | 723+130%100% | 315r385+41.4%100% | 223−48.6%100% | 433+581%100% | 64+56.3%100% | 41—100% | |
| Cost of revenue | 2.7−43.6%0.4% | 4.8−84.7%1.0% | 32−56.2%13.9% | 72−59.0%28.1% | 175+76.4%24.3% | 99+334%31.6% | 23−9.1%10.3% | 25−15.3%5.8% | 30−34.8%46.7% | 46—112% | |
| Gross profit | 703+53.1%99.6% | 459+136%99.0% | 195+6.1%86.1% | 184−66.5%71.9% | 547+154%75.7% | 215r285+7.9%68.4% | 200−51.1%89.7% | 408+1104%94.2% | 34—53.3% | −4.9—−12.0% | |
| Research and development | 8,239+249%1167% | 2,361−35.6%508% | 3,667+99.0%1621% | 1,843+45.9%721% | 1,263+226%175% | 387−30.3%123% | 556+12.8%250% | 493+810%114% | 54+500%85.1% | 9.0—22.2% | |
| General and administrative | 4,345+12.8%616% | 3,852+25.8%830% | 3,062−38.3%1354% | 4,960r5,725−0.2%1942% | 4,971+25.0%688% | 3,977r293+1238%1263% | 297+36.6%134% | 218+67.8%50.2% | 130r119−3.0%204% | 134r12—328% | |
| Operating expenses | 12,584+103%1783% | 6,213−7.7%1338% | 6,729−1.1%2975% | 6,803r7,567+9.1%2664% | 6,234+42.8%863% | 4,364r4,370+0.1%1386% | 4,358−37.9%1958% | 7,017+257%1620% | 1,963+54.3%3085% | 1,272—3125% | |
| Operating income | −11,881—−1683% | −5,753—−1239% | −6,534—−2889% | −6,619r−7,384—−2592% | −5,687—−787% | — | — | — | — | −1,277—−3137% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 6.0+167%9.5% | 2.3—5.5% | |
| Net interest income | — | 14−66.9%3.1% | 43—19.1% | — | — | — | — | — | — | — | |
| Non-interest income | — | — | 43—19.1% | 0—0.0% | — | — | — | — | — | — | |
| Other non-operating income (expense) | −31—−4.3% | −56—−12.0% | −179—−78.9% | −765—−299% | — | — | — | — | — | — | |
| Income before tax | −11,911—−1687% | −5,809—−1251% | −6,713—−2967% | −7,384—−2891% | −4,170—−577% | −3,987—−1267% | −4,158—−1868% | −6,609r−6,296—−1525% | −1,933—−3038% | −1,267—−3113% | |
| Income tax | — | — | — | 0−100%0.0% | 6.1+163%0.8% | 2.3−86.9%0.7% | 18r0—7.9% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | — | — | — | −7,384—−2891% | −4,164r−5,687—−576% | −4,149r−4,085—−1318% | −4,158—−1868% | −6,609—−1525% | −1,929—−3032% | −1,277—−3137% | |
| Income from discontinued operations | — | — | — | 0—0.0% | −22−134%−3.0% | 64—20.4% | — | — | — | 0—0.0% | |
| Net income including minority interests | −11,911—−1687% | −5,809—−1251% | −6,713—−2967% | −7,384r7,384−276%−2891% | 4,186—579% | — | — | — | — | — | |
| Minority interests' share of net income | −9.6—−1.4% | −13—−2.9% | −48—−21.1% | −114—−44.8% | −159—−22.0% | −151—−47.8% | −59—−26.5% | −10—−2.4% | −60—−94.6% | −62—−153% | |
| Net income attributable to shareholders | −11,902—−1686% | −5,795—−1248% | −6,665—−2946% | −7,269—−2846% | −4,027r−4,186—−557% | −4,085—−1298% | −4,158—−1868% | −6,609—−1525% | −1,929—−3032% | −1,277—−3137% | |
| Earnings per share, basic | — | — | — | — | -0.95—— | -1.47r-0.05—— | -0.05—— | -0.09—— | -0.03—— | -0.03—— | |
| Earnings per share, diluted | -0.66—— | -0.47—— | -1.01—— | — | -0.95—— | -1.47r-0.05—— | -0.05—— | -0.09—— | -0.03—— | -0.03—— | |
| Shares, weighted average (diluted) | 18+45.3%— | 12+87.2%— | 6.6—— | — | 4.4+58.3%— | 2.8r83−96.4%— | 78+9.6%— | 71+20.8%— | 59+34.0%— | 44—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1,802−72.3%43.2% | 6,500+381%73.3% | 1,352−76.7%43.8% | 5,813−46.8%74.2% | 10,918+744%82.3% | 1,294+0.7%45.7% | 1,285−25.6%48.0% | 1,727−31.8%71.0% | 2,533+2612%88.6% | 93—16.5% | |
| Short-term investments | 143r22+157%3.4% | 56−55.6%0.6% | 126−63.8%4.1% | 347−58.3%4.4% | 834+4216%6.3% | 19−69.9%0.7% | 64+533%2.4% | 10—0.4% | 0—0.0% | — | |
| Receivables | 368+138%8.8% | 154+21.9%1.7% | 127r175−37.2%4.1% | 202−41.1%2.6% | 342+9.1%2.6% | 314r314+14.9%11.1% | 273+2.8%10.2% | 266+487%10.9% | 45−65.4%1.6% | 131—23.1% | |
| Inventory | — | — | 0−100%0.0% | 38+29.6%0.5% | 30−74.6%0.2% | 117−8.3%4.1% | 127+46.0%4.8% | 87+29.9%3.6% | 67−50.1%2.3% | 135—23.8% | |
| Other current assets | 1,133−4.7%27.1% | 1,188+117%13.4% | 547—17.7% | — | — | — | — | 194+29.4%8.0% | 150−0.8%5.2% | 151—26.6% | |
| Current assets | 3,468−56.1%83.1% | 7,898+267%89.1% | 2,151r2,200−69.2%69.8% | 6,978−43.9%89.1% | 12,443+546%93.8% | 1,926r1,926+5.9%68.1% | 1,819−20.4%68.0% | 2,284−18.3%93.9% | 2,795+448%97.7% | 510—90.0% | |
| Property, plant and equipment | 228−10.4%5.5% | 255+0.2%2.9% | 254−19.4%8.2% | 316−14.3%4.0% | 368−23.8%2.8% | 483r483−18.2%17.1% | 591+47698%22.1% | 1.2−33.4%0.1% | 1.9−25.0%0.1% | 2.5—0.4% | |
| Right-of-use (leased) assets | 107r135−36.2%2.6% | 1670.0%1.9% | 167—5.4% | — | 91−28.3%0.7% | 127—4.5% | 0—0.0% | — | — | — | |
| Other intangible assets | 308−40.4%7.4% | 517+11.7%5.8% | 463—15.0% | — | — | 292+10.1%10.3% | 265+80.9%9.9% | 147+133%6.0% | 63+16.4%2.2% | 54—9.5% | |
| Non-current assets | 707−27.1%16.9% | 970+4.0%10.9% | 933r884+8.9%30.2% | 856+3.9%10.9% | 824−8.7%6.2% | 902+5.4%31.9% | 856+480%32.0% | 148+128%6.1% | 65+14.5%2.3% | 56—10.0% | |
| Total assets | 4,175−52.9%100% | 8,868+188%100% | 3,084−60.6%100% | 7,834−41.0%100% | 13,267+369%100% | 2,828r2,828+5.7%100% | 2,675+10.0%100% | 2,432−15.0%100% | 2,860+405%100% | 567—100% | |
| Accounts payable | 1,463+37.2%35.0% | 1,066+344%12.0% | 240+58.4%7.8% | 151+43.6%1.9% | 105r101+21.4%0.8% | 87−36.3%3.1% | 136+281%5.1% | 36r36+9.9%1.5% | 33−63.8%1.1% | 90—15.9% | |
| Current liabilities | 1,493+35.8%35.8% | 1,099+311%12.4% | 268+38.0%8.7% | 194+26.6%2.5% | 153−32.2%1.2% | 226r226+22.4%8.0% | 185+323%6.9% | 44−52.7%1.8% | 92−78.7%3.2% | 434—76.6% | |
| Lease liabilities (non-current) | 79−27.8%1.9% | 109—1.2% | — | — | 50−44.1%0.4% | 89—3.2% | — | — | — | — | |
| Non-current liabilities | — | — | — | 7.4−85.2%0.1% | 50−58.4%0.4% | 120—4.2% | — | — | — | — | |
| Total liabilities | 1,572+30.1%37.7% | 1,209+199%13.6% | 404+101%13.1% | 201−0.9%2.6% | 203−41.2%1.5% | 346r346+87.5%12.2% | 185+323%6.9% | 44−52.7%1.8% | 92−80.7%3.2% | 479—84.5% | |
| Retained earnings | −63,461—−1520% | −51,559—−581% | −45,763—−1484% | −39,099—−499% | −31,829—−240% | −27,802—−983% | −23,868—−892% | −19,769—−813% | −13,170—−460% | −11,301—−1994% | |
| Shareholders' equity | 2,990−62.8%71.6% | 8,036+164%90.6% | 3,044−61.7%98.7% | 7,949−39.2%101% | 13,064r13,064+426%98.5% | 2,482r2,525−0.3%87.8% | 2,491r2,383+4.3%93.1% | 2,388−13.7%98.2% | 2,768r3,006+940%96.8% | 266—47.0% | |
| Minority interests | −387—−9.3% | −377—−4.3% | −364—−11.8% | −316—−4.0% | −202—−1.5% | −43−140%−1.5% | 108—4.0% | — | −238—−8.3% | −178—−31.5% | |
| Total equity | 2,603−66.0%62.3% | 7,659+186%86.4% | 2,680−64.9%86.9% | 7,632−41.6%97.4% | 13,064+426%98.5% | 2,482r2,482−0.3%87.8% | 2,491r2,491+4.3%93.1% | 2,388−13.7%98.2% | 2,768+3054%96.8% | 88—15.5% | |
| Total liabilities and equity | 4,175−52.9%100% | 8,868+188%100% | 3,084−60.6%100% | 7,834−41.0%100% | 13,267+369%100% | 2,828r2,828+5.7%100% | 2,675+10.0%100% | 2,432−15.0%100% | 2,860+405%100% | 567—100% | |
| Shares outstanding | 200.0%— | 20r16+142%— | 8.1+36.0%— | 6.0+3.9%— | 5.7r5.7+90.8%— | 3.0r90−96.2%— | 79+4.3%— | 76+11.1%— | 68+32.5%— | 51r51—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 51+20.7%7.3% | 42r76−70.8%9.1% | 145+41.5%64.3% | 103−8.1%40.2% | 112—15.5% | — | — | — | — | — | |
| Share-based compensation | 859+74.6%122% | 492+189%106% | 170−77.4%75.3% | 753+83.6%295% | 410−64.0%56.7% | 1,139+81.8%362% | 627−75.9%282% | 2,602+2202%601% | 113−7.4%178% | 122—300% | |
| Cash from operating activities | −10,450—−1480% | −4,959—−1068% | −5,881—−2600% | −4,879—−1910% | −3,990—−552% | −2,619r−2,663—−832% | −3,006—−1350% | −2,518—−581% | −1,546—−2429% | −661—−1623% | |
| Capital expenditure | −25—−3.5% | −43—−9.3% | −34—−14.9% | −49—−19.3% | — | 0—0.0% | −646—−290% | — | 0—0.0% | −3.1—−7.6% | |
| Intangible assets bought | −75—−10.6% | −146—−31.4% | −136—−60.1% | −131—−51.5% | −79—−11.0% | −34—−10.7% | −123—−55.2% | −85—−19.7% | −9.7—−15.2% | −17—−41.8% | |
| Cash from investing activities | −243—−34.4% | −189—−40.6% | −170—−75.0% | −181−193%−70.7% | 194—26.8% | −27—−8.5% | −769—−346% | −155—−35.9% | −9.7—−15.2% | −20—−49.4% | |
| Debt issued | — | — | — | — | — | 31—9.7% | — | — | — | — | |
| Debt repaid | — | — | — | 0—0.0% | −23—−3.1% | — | — | — | — | — | |
| Shares issued | 6,046+43.7%856% | 4,209—907% | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 6,046−41.4%856% | 10,315+549%2222% | 1,590—703% | −45−100%−17.5% | 13,420+406%1857% | 2,654r2,699−20.4%843% | 3,333+78.5%1497% | 1,867−53.3%431% | 3,996+677%6278% | 514—1263% | |
| Exchange-rate effect on cash | −51—−7.2% | −20—−4.3% | — | — | — | — | — | — | — | — | |
| Change in cash | −4,698−191%−665% | 5,148—1109% | −4,461—−1972% | — | 9,624+111782%1332% | 8.6—2.7% | −442—−199% | −806−133%−186% | 2,440—3834% | −167—−409% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to May 31, 2026 | Q3 FY2026to May 31, 2026 | Q2 FY2026to Feb 28, 2026 | Q1 FY2026to Nov 30, 2025 | Q4 FY2025to Aug 31, 2025 | Q3 FY2025to May 31, 2025 | Q2 FY2025to Feb 28, 2025 | Q1 FY2025to Nov 30, 2024 | Q4 FY2024to Aug 31, 2024 | Q3 FY2024to May 31, 2024 | Q2 FY2024to Feb 29, 2024 | Q1 FY2024to Nov 30, 2023 | Q4 FY2023to Aug 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 194−68.5%100% | 0−100%— | 20−88.5%100% | 0−100%— | 174*+107%100% | 174+107%100% | 174+20.0%100% | 184+21.6%100% | 84*+173%100% | 84—100% | 145—100% | 151—100% | 31*—100% | |
| Cost of revenue | 0−100%0.0% | 0—— | 0—0.0% | 0−100%— | 0*—0.0% | 0—0.0% | 0—0.0% | 2.7−43.6%1.5% | 0*—0.0% | 0—0.0% | 0—0.0% | 4.8—3.2% | 0*—0.0% | |
| Gross profit | 194−68.4%100% | 0−100%— | 20−88.5%100% | 0−100%— | 174*+107%100% | 174+107%100% | 174+20.0%100% | 181+23.7%98.5% | 84*+173%100% | 84—100% | 145—100% | 146—96.8% | 31r−3.4*—100% | |
| Research and development | 4,000−45.4%2062% | 971−64.3%— | 475−71.8%2377% | 671−65.6%— | 1,882*+94.6%1082% | 2,718+374%1562% | 1,686+586%969% | 1,953+240%1062% | 967*+93.3%1151% | 573—682% | 246—170% | 574—380% | 500*—1628% | |
| General and administrative | 3,902−16.7%2011% | 1,023−15.2%— | 997−19.6%4983% | 902−1.8%— | 980*−25.7%563% | 1,207−3.7%694% | 1,239+118%712% | 919+29.2%499% | 1,320*+105%1571% | 1,254—1493% | 567—391% | 711—470% | 644r567*—2096% | |
| Operating expenses | 7,902−34.2%4073% | 1,994−49.2%— | 1,472−49.7%7360% | 1,574−45.2%— | 2,863*+25.2%1645% | 3,924+115%2255% | 2,925+260%1681% | 2,872+123%1561% | 2,287*+99.8%2723% | 1,827—2175% | 813—561% | 1,286—850% | 1,145r1,067*—3724% | |
| Operating income | −7,708—−3973% | −1,994—— | −1,452—−7260% | −1,574—— | −2,689*—−1545% | −3,750—−2155% | −2,751—−1581% | −2,691—−1463% | −2,203*—−2623% | −1,743—−2075% | −668—−461% | −1,139—−753% | −1,114*—−3624% | |
| Net interest income | — | — | — | — | — | — | — | — | 7.0*−22.4%8.3% | 0—0.0% | −0.0—−0.0% | — | 9.0*—29.3% | |
| Non-interest income | — | — | — | — | — | — | — | — | — | — | — | 7.3—4.8% | — | |
| Other non-operating income (expense) | −28—−14.5% | 0.8—— | 1.8−94.8%8.8% | −22—— | −8.6*−152%−5.0% | −40—−23.1% | 34+123%19.6% | −16—−8.7% | 16*—19.6% | −41—−49.3% | 15—10.5% | −46—−30.3% | −135*—−439% | |
| Income before tax | — | −1,993—— | — | — | −2,697*—−1550% | −3,791—−2179% | — | — | — | — | — | — | — | |
| Income tax | — | 0.0—— | 2.6—13.0% | 1.8—— | — | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Net income including minority interests | −7,740—−3990% | −1,993—— | −1,453—−7264% | −1,598—— | −2,697*—−1550% | −3,791—−2179% | −2,717—−1561% | −2,707—−1472% | −2,187*—−2603% | −1,784—−2124% | −653—−450% | −1,185—−783% | −1,249*—−4063% | |
| Minority interests' share of net income | −8.4—−4.3% | −1.8—— | −2.8—−13.8% | −2.5—— | −1.4*—−0.8% | −1.5—−0.9% | −3.8—−2.2% | −2.9—−1.6% | −1.8*—−2.1% | −2.6—−3.1% | −3.2—−2.2% | −5.7—−3.8% | −9.7*—−31.5% | |
| Net income attributable to shareholders | −7,732—−3986% | −1,991—— | −1,450—−7250% | −1,595—— | −2,696*—−1549% | −3,789—−2178% | −2,713—−1559% | −2,704—−1470% | −2,185*—−2601% | −1,782—−2121% | −650—−448% | −1,179—−780% | −1,239*—−4031% | |
| Earnings per share, diluted | — | -0.08—— | -0.06—— | -0.07—— | — | -0.21—— | -0.15—— | -0.16—— | — | -0.13—— | -0.06—— | -0.13—— | — | |
| Shares, weighted average (diluted) | 25+35.6%— | 25+35.6%— | 24+39.6%— | 21+28.2%— | — | 18+32.1%— | 18+62.7%— | 17+84.2%— | — | 14—— | 11—— | 9.1—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3,500—73.2% | 3,500−23.9%73.2% | 5,100−21.5%78.6% | 4,300−46.8%71.1% | 1,802−72.3%43.2% | 4,600−45.6%68.2% | 6,500+38.1%74.9% | 8,078+313%82.5% | 6,500+381%73.3% | 8,459—84.4% | 4,705—74.1% | 1,954—53.9% | 1,352—43.8% | |
| Short-term investments | 142—3.0% | 142+324%3.0% | 141+91.1%2.2% | 143+259%2.4% | 143r22+157%3.4% | 34−27.6%0.5% | 74−15.7%0.9% | 40−44.9%0.4% | 56−55.6%0.6% | 46—0.5% | 88—1.4% | 72—2.0% | 126—4.1% | |
| Receivables | 49—1.0% | 49−86.3%1.0% | 42−87.3%0.6% | 88−66.6%1.5% | 368+138%8.8% | 358+71.8%5.3% | 331−7.3%3.8% | 263−50.7%2.7% | 154+21.9%1.7% | 208—2.1% | 357—5.6% | 535—14.7% | 127r175—4.1% | |
| Inventory | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other current assets | 399—8.3% | 399−51.6%8.3% | 459−46.0%7.1% | 851+91.5%14.1% | 1,133−4.7%27.1% | 823+117%12.2% | 850+219%9.8% | 444—4.5% | 1,188+117%13.4% | 380—3.8% | 267—4.2% | — | 547—17.7% | |
| Current assets | 4,065—85.0% | 4,065−30.0%85.0% | 5,770−25.3%88.9% | 5,363−39.2%88.6% | 3,468−56.1%83.1% | 5,807−36.1%86.1% | 7,724+42.6%89.0% | 8,826+228%90.1% | 7,898+267%89.1% | 9,093—90.8% | 5,417—85.3% | 2,694—74.3% | 2,151r2,200—69.8% | |
| Property, plant and equipment | 229—4.8% | 229−4.6%4.8% | 243−7.2%3.7% | 216−20.1%3.6% | 228−10.4%5.5% | 240+9.5%3.6% | 262+15.7%3.0% | 271+15.8%2.8% | 255+0.2%2.9% | 219—2.2% | 226—3.6% | 234—6.4% | 254—8.2% | |
| Right-of-use (leased) assets | 84—1.8% | 84−46.1%1.8% | — | — | 107r135−36.2%2.6% | 157+9.4%2.3% | 157+4.5%1.8% | — | 1670.0%1.9% | 143—1.4% | 150—2.4% | — | 167—5.4% | |
| Other intangible assets | 339—7.1% | 339−34.4%7.1% | 318−37.2%4.9% | 308−39.0%5.1% | 308−40.4%7.4% | 516—7.7% | 506—5.8% | 505—5.2% | 517+11.7%5.8% | — | — | — | 463—15.0% | |
| Non-current assets | 716—15.0% | 716−23.3%15.0% | 717−24.8%11.1% | 688−29.0%11.4% | 707−27.1%16.9% | 935+1.0%13.9% | 953+1.9%11.0% | 968+3.7%9.9% | 970+4.0%10.9% | 925—9.2% | 935—14.7% | 933—25.7% | 933r884—30.2% | |
| Total assets | 4,781—100% | 4,781−29.1%100% | 6,487−25.2%100% | 6,051−38.2%100% | 4,175−52.9%100% | 6,741−32.7%100% | 8,678+36.6%100% | 9,794+170%100% | 8,868+188%100% | 10,018—100% | 6,352—100% | 3,627—100% | 3,084—100% | |
| Accounts payable | 350—7.3% | 350−76.0%7.3% | 183−89.8%2.8% | 1,425+430%23.6% | 1,463+37.2%35.0% | 1,458+1032%21.6% | 1,793+3141%20.7% | 269+172%2.7% | 1,066+344%12.0% | 129—1.3% | 55—0.9% | 99—2.7% | 240—7.8% | |
| Current liabilities | 383—8.0% | 383−74.2%8.0% | 215−88.2%3.3% | 1,457+389%24.1% | 1,493+35.8%35.8% | 1,488+854%22.1% | 1,822+2130%21.0% | 298+139%3.0% | 1,099+311%12.4% | 156—1.6% | 82—1.3% | 125—3.4% | 268—8.7% | |
| Lease liabilities (non-current) | 54—1.1% | 54−38.1%1.1% | 62−34.0%1.0% | 71−30.5%1.2% | 79−27.8%1.9% | 87—1.3% | 94—1.1% | 102—1.0% | 109—1.2% | — | — | — | — | |
| Total liabilities | 437—9.1% | 437−72.2%9.1% | 277−85.5%4.3% | 1,527+282%25.2% | 1,572+30.1%37.7% | 1,575+480%23.4% | 1,917+839%22.1% | 400+57.3%4.1% | 1,209+199%13.6% | 271—2.7% | 204—3.2% | 254—7.0% | 404—13.1% | |
| Retained earnings | −68,497—−1433% | −68,497—−1433% | −66,506—−1025% | −65,056—−1075% | −63,461—−1520% | −60,765—−901% | −56,976—−657% | −54,262—−554% | −51,559—−581% | −49,374—−493% | −47,592—−749% | −46,943—−1294% | −45,763—−1484% | |
| Shareholders' equity | 4,738—99.1% | 4,738−14.7%99.1% | 6,602−7.6%102% | 4,913−49.7%81.2% | 2,990−62.8%71.6% | 5,552−45.2%82.4% | 7,145+9.6%82.3% | 9,774+161%99.8% | 8,036+164%90.6% | 10,123—101% | 6,521—103% | 3,742—103% | 3,044—98.7% | |
| Minority interests | −394—−8.2% | −394—−8.2% | −392—−6.0% | −389—−6.4% | −387—−9.3% | −386—−5.7% | −384—−4.4% | −380—−3.9% | −377—−4.3% | −376—−3.7% | −373—−5.9% | −370—−10.2% | −364—−11.8% | |
| Total equity | 4,344—90.9% | 4,344−15.9%90.9% | 6,210−8.1%95.7% | 4,523−51.8%74.8% | 2,603−66.0%62.3% | 5,167−47.0%76.6% | 6,761+10.0%77.9% | 9,394+179%95.9% | 7,659+186%86.4% | 9,747—97.3% | 6,148—96.8% | 3,373—93.0% | 2,680—86.9% | |
| Total liabilities and equity | 4,781—100% | 4,781−29.1%100% | 6,487−25.2%100% | 6,051−38.2%100% | 4,175−52.9%100% | 6,741−32.7%100% | 8,678+36.6%100% | 9,794+170%100% | 8,868+188%100% | 10,018—100% | 6,352—100% | 3,627—100% | 3,084—100% | |
| Shares outstanding | 25—— | 25+27.4%— | 25+42.6%— | 22+27.3%— | 200.0%— | 19+23.1%— | 17+40.9%— | 17+69.3%— | 20r16+142%— | 16—— | 12—— | 10—— | 8.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 52−6.6%26.8% | 14*−36.0%— | 14*+60.4%70.0% | 12+37.5%— | 12*−26.6%6.9% | 22*+44.3%12.5% | 8.7*−45.2%5.0% | 8.7−69.7%4.7% | 16*−76.9%19.5% | 15*—17.9% | 16*—11.0% | 29—19.0% | 71*—231% | |
| Share-based compensation | 365−56.1%188% | 93*−80.2%— | 75*−55.2%374% | 75−24.7%— | 123*+27.2%70.5% | 470*+37.6%270% | 167*—96.1% | 99+84.3%54.1% | 97*+902%115% | 342—407% | 0*—0.0% | 54—35.7% | 9.6*—31.3% | |
| Cash from operating activities | −7,425—−3828% | −1,635*—— | −2,164*—−10819% | −984—— | −2,642*—−1519% | −3,584*—−2060% | −1,498*—−861% | −2,726—−1482% | −1,892*—−2252% | −1,266*—−1507% | −620*—−427% | −1,182—−781% | −1,622*—−5275% | |
| Capital expenditure | −41—−21.0% | 0*—— | −41*—−204% | 0—— | −0.0*—−0.0% | — | −0.0*—−0.0% | −25—−13.4% | −43*—−51.2% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Intangible assets bought | −61—−31.5% | −26*—— | −15*—−75.5% | −5.1—— | −15*—−8.4% | −19*—−11.2% | −28*—−16.0% | −13—−7.2% | −27*—−31.6% | −22*—−26.2% | −57*—−39.3% | −40—−26.5% | −68*—−223% | |
| Cash from investing activities | −244—−126% | −27*—— | −54*—−270% | −5.1—— | −158*—−90.7% | −19*—−11.2% | −28*—−16.0% | −38—−20.6% | −70*—−82.8% | −22*—−26.2% | −57*—−39.3% | −40—−26.5% | −68*—−223% | |
| Shares issued | 6,518+7.8%3360% | 0*−100%— | 3,044*+25873%15220% | 3,474−20.1%— | 0*—0.0% | 1,689*—971% | 12*−99.6%6.7% | 4,345+248%2363% | 0*—0.0% | 0*—0.0% | 2,961r492*—2042% | 1,248r572—825% | — | |
| Cash from financing activities | 6,518+7.8%3360% | 0*−100%— | 3,044*+25873%15220% | 3,474−20.1%— | 0*—0.0% | 1,689*−66.5%971% | 12*−99.7%6.7% | 4,345+139%2363% | 0*—0.0% | 5,043*—6004% | 3,453*—2381% | 1,819—1203% | −122*—−396% | |
| Exchange-rate effect on cash | 35—17.8% | 9.0*−75.9%— | 21*—103% | −5.7—— | 11*+424%6.2% | 37*—21.4% | −95*—−54.7% | −3.2−173%−1.7% | 2.1*—2.4% | −1.2*—−1.5% | −25*—−17.2% | 4.4—2.9% | — | |
| Change in cash | −1,117—−576% | −1,653*—— | 847*—4235% | 2,479+57.1%— | −2,790*—−1603% | −1,877*−150%−1079% | −1,609*−158%−925% | 1,578+162%858% | −1,959*—−2332% | 3,754*—4469% | 2,751*—1897% | 602—398% | −1,812*—−5894% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of May 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Lexaria Bioscience Corp. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- IP Licensing$1 M99%+52%
- B2B$0 M1.4%+0.0%
Business segments
- [IP Licensing [Member]]$1 M99%+52%
Source: SEC annual report (XBRL data) · as of Aug 31, 2025
Executive pay at Lexaria Bioscience Corp.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Richard Christopher | $893 K | $497 K | $386 K | — |
| 2024Richard Christopher | $1.4 M | $1.7 M | $296 K | — |
| 2023Richard Christopher | $288 K | $157 K | $237 K | — |
Source: SEC proxy statement (Form DEF 14A) · as of Aug 31, 2025
Events at Lexaria Bioscience Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 4 · Material agreement 11 · Agreement ended 1 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Agreement ended | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2025 | $4 M | Private placement after listing | $2 to $10 million | 5 | options | SEC |
| Sep 2025 | $4 M | Private placement after listing | $2 to $10 million | 5 | options | SEC |
| Oct 2024 | $5 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Feb 2024 | $4 M | Private placement after listing | $2 to $10 million | 2 | options | SEC |
| Oct 2023 | $2 M | Private placement after listing | Under $2 million | 1 | options | SEC |
| Dec 2021 | $1 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| May 2020 | $2 M | Private placement after listing | $2 to $10 million | 21 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Lexaria Bioscience Corp. compares in Biotechnology
- Market cap$15 M · higher than 14% of 726
- Revenue$1 M · higher than 22% of 647
- Revenue growth54.4% · higher than 73% of 438
- Price / sales21.1× · lower than 31% of 339
- Price / book5.0× · lower than 31% of 534
- FCF yield-69.8% · higher than 17% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lexaria Bioscience Corp.🇨🇦 | $15 M | — | — | +54.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending August-2025
- Balance sheet:
- As of August-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lexaria Bioscience Corp.? Verify and update this profile — free
Show Lexaria Bioscience Corp.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.